Artificial Pancreas Center
The Artificial Pancreatic Center (APC) is dedicated to improving glycemic management through the development and testing of glucose-sensing technologies and drug delivery systems to ultimately achieve a fully automated artificial endocrine pancreas. Over the years the laboratory has gained expertise in development and testing of medical devices using a bench to bedside approach. The laboratory has close collaborations with engineers from industry and other academic faculty and uses small and large animals to implant and test hardware. The laboratory faculty have been training graduate students who become intimately involved in numerous projects while developing skills in surgery, implantation biology, pharmacology, study design and biostatistics.
An artificial endocrine pancreas consists of a continuous glucose monitoring system, an insulin infusion pump, a glucose/glucagon infusion pump and a computer controller. Such a system will decrease errors in insulin delivery, eliminate the risk for hypoglycemia and improve a diabetic person’s quality of life. Intensive insulin therapy and near-normal blood glucose control has been shown to decrease morbidity and mortality leading to improved long-term clinical outcome and decreased cost.
Our multidisciplinary team of physicians, engineers, scientists, nurses, dieticians, pharmacists and veterinarians are currently developing systems for both ambulatory patients with diabetes and hospitalized patients with diabetes or stress-induced hyperglycemia.
Our Mission is to become a world-leading laboratory for (1) medical device research, development, and testing, (2) education of medical students, resident physicians, fellows and faculty how to develop medical devices and perform animal/human research, and (3) research, development and clinical application of an artificial pancreas for hospitalized patients and ambulatory patients with diabetes.
The Artificial Pancreas Center was founded in 1998 with support from the Department of Anesthesiology, Sidney Kimmel Medical College and Thomas Jefferson University. Under the direction of Jeffrey I Joseph, DO, the center sought to facilitate the research and development of technology for the real-time monitoring and control of blood glucose and insulin levels in patients with diabetes. Initial work within the center focused on the development of an implantable optical blood glucose sensor in collaboration with Animas Corporation, a company Dr. Joseph helped found in 1996.